94.17 +0.86 (0.92%)
Pre-Market: 7:30AM EDT
|Bid||94.14 x 1200|
|Ask||94.23 x 800|
|Day's Range||92.90 - 93.66|
|52 Week Range||72.30 - 93.89|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||17.34|
|Forward Dividend & Yield||2.83 (3.03%)|
|1y Target Est||104.00|
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]
How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.
Moody's Investors Service has assigned a Baa2 long-term issuer rating to Alcon Inc. ("Alcon" or "the company"). This is the first time that Moody's assigned ratings to Alcon, a global manufacturer of eye care medical equipment and products which is being spun off from Novartis AG (Novartis, A1 stable).
Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened ...
Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday. "Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange," Novartis said in a statement, adding that Alcon would enter the SMI, Switzerland's blue-chip stock index, on its first trading day. Novartis said Alcon had secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS were advising Novartis on the transaction.
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
As it builds out high-profile biotech developments on the Peninsula, BioMed Realty is digging into the East Bay in a big way. The San Diego-based unit of Blackstone Group LP (NYSE: BX) paid about $135 million for the six-story, 250,000-square-foot structure, the company said Wednesday, which includes an adjacent space for as much as 850,000 square feet of additional lab and office space. "We plan to offer in excess of 1 million square feet of space to innovative tenants, including biotech and other laboratory users," Denis Sullivan, executive vice president and chief investment officer for BioMed, said in a statement.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.
Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.
The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.